Back to Stakeholders
Categories

1 domain / 2 areas / 1 specialization

Ark Invest

Data updated

New York, New York, United States

ARK Invest, legally ARK Investment Management LLC, is an active investment manager founded by Cathie Wood in 2014. It is based in New York, United States, and focuses on disruptive innovation across public markets, with some private-market exposure through ARK Venture Fund.

ARK has published dedicated research on psychedelic therapeutics and the field’s clinical and commercial potential. Its public research and thematic investment approach make it a relevant institutional stakeholder for psychedelic drug development companies, especially those advancing novel therapies into clinical and public-market stages.

Investor Context

Institutional Investors

Investment Context

This stakeholder is listed as an Institutional Investor within Institutional Investors. Its public geography context is global. Public stage signals include Growth / Late Stage, Public Markets, and Multi-Stage. Public focus areas include Drug Development.

ARK Invest is best known for thematic, research-driven investing in disruptive innovation, with portfolios that span public equities and, through ARK Venture Fund, private/public crossover exposure. In psychedelics, ARK’s relevance comes primarily from its public research coverage of psychedelic therapeutics and its willingness to allocate to frontier life-science themes that may progress from development-stage companies into broader public-market strategies.

Investor Type

Institutional Investor

Geographic Scope

Global

Psychedelic Focus

Explicit Psychedelic Focus

Engagement

Active

Investment Stage Focus

Growth / Late StagePublic MarketsMulti-Stage

Investment Focus Areas

Drug Development

Investment Orientation

Engagement Status

Active

Investor Type

Institutional Investor

Investment Website

Quick Facts

Founded
2014
HQ
New York, New York, United States
Website
Visit